Polycarboxylic Acid Patents (Class 514/566)
  • Patent number: 10953024
    Abstract: The use of an emulsion for protecting the skin against aggressive chemical agents, wherein this emulsion includes at least one amphoteric chelating agent which includes a complex based on aluminium and on ethylenediaminetetraacetic acid or the trisodium salt thereof, having the general formula [Al(Y)Bn]c?Dc with B being OH?, BO2? or H+, Y being a tetracarboxylate which can be protonated four times to form ethylenediaminetetraacetic acid, n being an integer equal to 0, 1, 2 or 3, D being a counterion, preferably Na+, c being an integer equal to 0, 1, 2 or 3 and c? being a relative number having the same absolute value as c.
    Type: Grant
    Filed: July 17, 2013
    Date of Patent: March 23, 2021
    Assignee: PREVOR INTERNATIONAL
    Inventors: Joel Blomet, Laurence Mathieu, Marie-Claude Meyer
  • Patent number: 10845346
    Abstract: Compositions, kits, and methods of using the kits and compositions to determine the hardness of and/or magnesium concentration in a solution are described. The kit can include a lyophilized composition that has an absorbance at a detectable wavelength in response to the hardness of the solution and or the concentration of magnesium in the solution.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: November 24, 2020
    Assignee: WATER LENS, LLC
    Inventors: Justin M. Dragna, Adam Garland, Tyler West
  • Patent number: 10662122
    Abstract: The present disclosure provides compositions comprising a ligand and a fertilizer, including kits comprising the ligand. The disclosure also provides method of growing a plant, wherein the method comprises the step of contacting the plant with a composition comprising a ligand.
    Type: Grant
    Filed: November 30, 2015
    Date of Patent: May 26, 2020
    Assignee: CHS Inc.
    Inventor: Brian Kuehl
  • Patent number: 10234448
    Abstract: Provided herein are methods for diagnosing impaired nutrient absorption or determining a nutrient absorption level in an individual. A first stable absorption isotopologue of a nutrient and a second stable absorption isotopolog of the same nutrient are administered orally and intravenously, respectively, to the individual. Amounts of the first and second isotopologs are both measured in blood samples drawn periodically and a ratio of the first isotopolog to the second isotopolog is calculated providing a level of nutrient absorption. The results are compared with a healthy control or an ideal value of 1.0. The ratio less than that of a healthy control or significantly lower than 1.0 indicates an impaired nutrient absorption in the individual.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: March 19, 2019
    Assignee: The Texas A&M University System
    Inventors: Nicolaas E. Deutz, Gerdien C. Ligthart-Melis, Marielle Engelen, Gabriella Ten Have
  • Patent number: 9714213
    Abstract: A compound represented by general formula (1) a pharmaceutically acceptable salt thereof or a solvate thereof; wherein Ar represents an aryl group, or a 5- or 6-membered heteroaryl group containing a nitrogen atom, an oxygen atom or a sulfur atom; Y represents, for example, a hydrogen atom or a C1-C6 alkyl group; A represents a C1-C3 alkylene chain which may be substituted with two C1-C2 alkyl groups; X represents a hydrogen atom or a halogen atom; V represents an oxygen atom or a methylene chain; and R represents a group selected from the formulae below:
    Type: Grant
    Filed: October 14, 2014
    Date of Patent: July 25, 2017
    Assignee: TOA EIYO LTD.
    Inventors: Kazuhiro Uemoto, Yoshimichi Sato, Naoki Okada, Emiko Iimori, Masayuki Kageyama
  • Patent number: 9375024
    Abstract: A process for producing powdered cocoa shells as a food ingredient, as replacer for cocoa powder, to impart coloration in food products, and as fat bloom inhibitor in cocoa-based products.
    Type: Grant
    Filed: June 26, 2013
    Date of Patent: June 28, 2016
    Inventors: Herwig Bernaert, Ive De Ruysscher
  • Patent number: 9301945
    Abstract: The disclosure is directed to methods for treating inflammatory conditions and cancers that have misregulated NF-?B. In some embodiments, the disclosure is directed to methods for treating inflammatory conditions, inflammatory states associated with treating HIV and AIDS infections, and cancers that include administering strontium ranelate to a subject diagnosed with or at risk of inflammatory conditions, inflammatory states, and cancers, respectively.
    Type: Grant
    Filed: July 19, 2012
    Date of Patent: April 5, 2016
    Assignee: Emory University
    Inventors: M. Neale Weitzmann, Masayoshi Yamaguchi
  • Patent number: 9040553
    Abstract: The present invention provides a process for the synthesis of substituted phenoxymethylpropionic acid and related compounds. The compounds are useful for inhibiting the formation of AGEs (Advanced Glycation End Products).
    Type: Grant
    Filed: July 11, 2013
    Date of Patent: May 26, 2015
    Assignee: CELL VIABLE CORPORATION
    Inventors: Iraj Lalezari, Jill Fabricant
  • Publication number: 20150140113
    Abstract: The present invention generally relates to dosage forms for oral administration including one or more gelling agents. In particular, the present invention is directed to gelling agent-based dosage forms that are easily administered and taken, or swallowed. The present invention is also directed to gelling agent-based dosage forms that exhibit relatively low syneresis, are thermally stable, exhibit substantially constant active ingredient concentration, and/or exhibit one or more advantageous rheological properties. In particular, the present invention is directed to such gels containing one or more omega-3 fatty acids. The gelling agent-based dosage forms of the present invention are suitable for administration of a relatively large dose of active ingredient. The gelling agent-based dosage forms of the present invention are also suitable for administration of multiple active ingredients.
    Type: Application
    Filed: March 19, 2013
    Publication date: May 21, 2015
    Applicant: PARTICLE DYNAMICS INTERNATIONAL, LLC
    Inventors: Irwin Jacobs, Stephen Gee, Paul Brady
  • Publication number: 20150133495
    Abstract: Disclosed herein is a compound of Formula I or a pharmaceutically acceptable salt thereof, in which A, G, R1 and R2 are as defined herein. The compounds and pharmaceutical compositions of the compounds are suitable for the treatment of HCV infection in mammals and are also useful to modulate or inhibit NS3/4 dimerization.
    Type: Application
    Filed: November 13, 2014
    Publication date: May 14, 2015
    Inventor: Daniel Lamarre
  • Publication number: 20150132384
    Abstract: Synthesis and characterization of starch based pH-responsive nanoparticles for controlled drug delivery are described. Polymethacrylic acid grafted starch (PMAA-g-St) nanoparticles with various molar ratio of starch to MAA were synthesized by a new one-pot method that enabled simultaneous grafting of PMAA and nanoparticle formation in an aqueous medium. NMR data showed that polysorbate 80 was polymerized into the graft polymer. Nanoparticles were relatively spherical with narrow size distribution and porous surface morphology and exhibited pH-dependent swelling in physiological pH range. The particle size and magnitude of volume phase transition were dependent on PMAA content and formulation parameters such as surfactant levels, cross-linker amount, and total monomer concentration. The results showed that the new pH-responsive nanoparticles possessed useful properties for controlled drug delivery.
    Type: Application
    Filed: March 4, 2013
    Publication date: May 14, 2015
    Inventors: Xiao Yu Wu, Alireza Shalviri, Ping Cai
  • Publication number: 20150119442
    Abstract: The present invention relates to biodegradable biocide agents against marine woodborers. In particular, the present invention relates to novel slow releasing biocide impregnating solutions against marine woodborers, and methods of creating anti marine woodborer environments.
    Type: Application
    Filed: May 22, 2014
    Publication date: April 30, 2015
    Applicant: Teredo Marine Protection ApS
    Inventor: Michael Igelso Hvidt
  • Publication number: 20150105465
    Abstract: Antiseptic compositions comprising at least one salt of EDTA are disclosed. These compositions have broad spectrum antimicrobial and antifungal activity and they also have anticoagulant properties. The antiseptic compositions have also demonstrated activity in penetrating and breaking down microbial slime, or biofilms. They are safe for human and medical uses and may be used as prophylactic preparations to prevent infection, or to reduce the proliferation of and/or eliminate existing or established infections.
    Type: Application
    Filed: November 7, 2014
    Publication date: April 16, 2015
    Inventors: Peter Kite, David Hatton
  • Publication number: 20150087582
    Abstract: Compositions comprising iron-sequestering glycoproteins, chelating agents, stabilizing agents, binding agents, surfactants, fluorides, antimicrobials and a pH adjuster or buffer for the prevention and treatment of oral cavity diseases caused by dental plaque/biofilm, such as dental caries, gingivitis and periodontitis, through anti-infective properties are disclosed. The anti-infective properties of a composition include reduction or killing of anaerobic/aerobic/facultative gram-negative and gram-positive oral bacteria occurring in polymicrobial dental biofilms. The composition may be in the form of wash, rinse, soak, paste, gel, spray, or other suitable form. Additionally, the invention offers an efficient method of delivering the formulated composition containing a PEGylated or fluorinated iron-sequestering glycoprotein and one or two chelating agents or chelating agents alone using either a liposomal or a nanoparticle delivery system.
    Type: Application
    Filed: June 27, 2012
    Publication date: March 26, 2015
    Inventors: Karen LoVetri, Srinivasa Madhyastha, Nandadeva Yakandawala, Purushottam V. Gawande, Gord Froehlich
  • Publication number: 20150079203
    Abstract: Antimicrobial compositions providing synergistic antimicrobial effects against a variety of bacterial, viral and fungal organisms are described. Methods for using the antimicrobial compositions and products containing the antimicrobial compositions are also described herein.
    Type: Application
    Filed: September 19, 2014
    Publication date: March 19, 2015
    Inventors: Joseph Paul Thomas, Zsolt Istvan Hertelendy, Michael Lisle Howell
  • Publication number: 20140371316
    Abstract: The present invention provides a process for the synthesis of substituted phenoxymethylpropiomc acid and related compounds. The compounds are useful for inhibiting the formation of AGEs (Advanced Glycation End Products).
    Type: Application
    Filed: November 23, 2012
    Publication date: December 18, 2014
    Inventors: Jill S. FABRICANT, Iraj LALEZARI
  • Patent number: 8911665
    Abstract: Antiseptic compositions comprising at least one salt of EDTA are disclosed. These compositions have broad spectrum antimicrobial and antifungal activity and they also have anticoagulant properties. The antiseptic compositions have also demonstrated activity in penetrating and breaking down microbial slime, or biofilms. They are safe for human and medical uses and may be used as prophylactic preparations to prevent infection, or to reduce the proliferation of and/or eliminate existing or established infections.
    Type: Grant
    Filed: January 3, 2014
    Date of Patent: December 16, 2014
    Inventors: Peter Kite, David Hatton
  • Publication number: 20140350045
    Abstract: The present invention provides a process for the synthesis of substituted phenoxymethylpropionic acid and related compounds. The compounds are useful for inhibiting the formation of AGEs (Advanced Glycation End Products).
    Type: Application
    Filed: July 11, 2013
    Publication date: November 27, 2014
    Inventors: IRAJ LALEZARI, JILL FABRICANT
  • Publication number: 20140343000
    Abstract: Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, C-17 and C-3 modified triterpenoids that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formulas I, II and III: These compounds are useful for the treatment of HIV and AIDS.
    Type: Application
    Filed: July 24, 2014
    Publication date: November 20, 2014
    Inventors: Alicia Regueiro-Ren, Zheng Liu, Jacob Swidorski, Ny Sin, Brian Lee Venables, Sing-Yuen Sit, Yan Chen, Jie Chen, Nicholas A. Meanwell
  • Patent number: 8877234
    Abstract: The invention relates to clear, liquid preservatives, which contain a) one or several 1-hydroxy-4-methyl-6-alkyl-2(1H)-pyridones and/or one or several salts thereof, wherein alkyl represents a linear, branched or cyclic alkyl group having 1-12 carbon atoms, and b) one or several alcohols containing one or several aromatic groups.
    Type: Grant
    Filed: January 25, 2006
    Date of Patent: November 4, 2014
    Assignee: Clariant Finance (BVI) Limited
    Inventors: Waltraud Simsch, {dot over (P)}eter Klug, Sonja Klein
  • Publication number: 20140314827
    Abstract: Described herein are compositions comprising at least one buffering agent, at least one chelating agent and at least one antimicrobial agent, which can be used for treating and/or preventing diseases or disorders in a variety of animals. In certain embodiments, in particular, the compositions can be used for treating and/or preventing ophthalmic and oral cavity diseases or disorders in dogs and cats and oropharyngeal and/or guttural pouch diseases or disorders in equines. In certain embodiments, the compositions can also be used for treating ophthalmic or oral cavity diseases or disorders in humans.
    Type: Application
    Filed: April 17, 2014
    Publication date: October 23, 2014
    Inventor: Steven A. Melman
  • Publication number: 20140271825
    Abstract: The present invention provides liposomes loaded with chelating agents, pharmaceutical formulations including these liposomes and methods of making chelating agent liposomes. Because the chelating agents are loaded in the liposome with high efficiencies, the liposomes are of use in treatment of metal ion overload in subjects. The liposomes can include two or more different chelating agents of different structures and affinities for metal ions.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Inventors: Mark E. HAYES, Charles O. NOBLE, Francis C. SZOKA, JR.
  • Publication number: 20140275258
    Abstract: Described herein is a method of delivering drugs to the blood stream directly by absorption through cell membranes in the wall of the rectum from a rectal suppository comprising a glyceride based excipient More specifically, CaNa2 EDTA is delivered rectally from a suppository containing water soluble, glyceride based excipient/carrier.
    Type: Application
    Filed: March 12, 2014
    Publication date: September 18, 2014
    Applicant: APPLIED BIORESEARCH, INC.
    Inventors: Robert A. Settineri, Ernest H. Pfadenhauer
  • Publication number: 20140275259
    Abstract: Described herein is a method of delivering hydrophilic drugs directly from a hydrophobic carrier and/or excipient to absorbing cell membranes. More specifically, CaNa2 EDTA is delivered rectally from a suppository containing methylbutylketone in a carrier as an excipient.
    Type: Application
    Filed: March 12, 2014
    Publication date: September 18, 2014
    Applicant: APPLIED BIORESEARCH, INC.
    Inventors: James F. Palmer, Robert A. Settineri
  • Publication number: 20140275260
    Abstract: The invention provides a process for preparing stable, high API content, solid pharmaceutical dosage forms by direct compression or dry granulation, characterized in that the pharmaceutical tablets rapidly disintegrate in water or other aqueous solutions to produce a clear or almost clear solution. Also provided is a pharmaceutical carglumic acid tablet, which has improved manufacturing, dissolution, and stability properties, and is less expensive to produce, compared to the equivalent commercial product.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Inventors: Sanjay Rangnathrao Kawale, Mahendra R. Patel
  • Patent number: 8828317
    Abstract: Antiseptic compositions comprising at least one salt of EDTA are disclosed. These compositions have broad spectrum antimicrobial and antifungal activity and they also have anticoagulant properties. The antiseptic compositions have also demonstrated activity in penetrating and breaking down microbial slime, or biofilms. They are safe for human and medical uses and may be used as prophylactic preparations to prevent infection, or to reduce the proliferation of and/or eliminate existing or established infections.
    Type: Grant
    Filed: January 3, 2014
    Date of Patent: September 9, 2014
    Inventors: Peter Kite, David Hatton
  • Publication number: 20140243725
    Abstract: An antimicrobial medical dressing provides a combination of antimicrobial agents in various concentrations that protect against microorganisms, absorb exudates, and promote healing. The antimicrobial agents may include compositions of ethanol, hydrogen peroxide, and/or ethylenediaminetetraacetic acid.
    Type: Application
    Filed: May 6, 2014
    Publication date: August 28, 2014
    Applicant: Hyprotek, Inc.
    Inventors: Patrick O. Tennican, L. Myles Phipps
  • Publication number: 20140221361
    Abstract: Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, C-19 modified triterpenoids that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formulas I and II: These compounds are useful for the treatment of HIV and AIDS.
    Type: Application
    Filed: February 4, 2014
    Publication date: August 7, 2014
    Inventors: Jacob Swidorski, Brian Lee Venables, Zheng Liu, Ny Sin, Nicholas A. Meanwell, Alicia Regueiro-Ren
  • Publication number: 20140194519
    Abstract: Antiseptic compositions comprising at least one salt of EDTA are disclosed. These compositions have broad spectrum antimicrobial and antifungal activity and they also have anticoagulant properties. The antiseptic compositions have also demonstrated activity in penetrating and breaking down microbial slime, or biofilms. They are safe for human and medical uses and may be used as prophylactic preparations to prevent infection, or to reduce the proliferation of and/or eliminate existing or established infections.
    Type: Application
    Filed: January 3, 2014
    Publication date: July 10, 2014
    Applicants: Aseptica, Inc.
    Inventors: Peter Kite, David Hatton
  • Publication number: 20140194518
    Abstract: Antiseptic compositions comprising at least one salt of EDTA are disclosed. These compositions have broad spectrum antimicrobial and antifungal activity and they also have anticoagulant properties. The antiseptic compositions have also demonstrated activity in penetrating and breaking down microbial slime, or biofilms. They are safe for human and medical uses and may be used as prophylactic preparations to prevent infection, or to reduce the proliferation of and/or eliminate existing or established infections.
    Type: Application
    Filed: January 3, 2014
    Publication date: July 10, 2014
    Applicant: ASEPTICA, INC.
    Inventors: Peter Kite, David Hatton
  • Publication number: 20140186408
    Abstract: Embodiments of the invention provide solid forms of magnesium glycinate dihydrate and compositions thereof, which are useful for treating hyperphosphatemia and which exhibit desirable characteristics for the same. The invention further provides processes for the production of solid forms of magnesium glycinate dihydrate.
    Type: Application
    Filed: November 26, 2013
    Publication date: July 3, 2014
    Applicant: Cypress Pharmaceutical, Inc.
    Inventor: Robert L. Lewis
  • Publication number: 20140179741
    Abstract: Disclosed herein are methods to promote axonal outgrowth of a neuron comprising, contacting the neuron with an effective amount of a chelating agent, to thereby promote axonal outgrowth in the neuron. Also disclosed are methods of treating a subject for a CNS lesion, comprising, administering to the subject a therapeutically effective amount of a chelating agent, Also disclosed are devices for promoting regeneration in a lesioned neuron, and pharmaceutical compositions comprising a therapeutically effective amount of a chelating agent formulated for localized administration directly to an injured neuron. Examples of such chelating agents are provided.
    Type: Application
    Filed: October 10, 2013
    Publication date: June 26, 2014
    Applicants: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Larry I. Benowitz, Stephen J. Lippard, Paul Rosenberg, Yiqing Li, Zhen Huang
  • Patent number: 8759397
    Abstract: The present invention provides a salt of ethylenediamine disuccinic acid comprising at least 1.6 mole of alkaline earth metal per mole of ethylenediamine disuccinic acid. Salts of the invention have been found to be useful in providing compositions comprising hydrogen peroxide having improved stability.
    Type: Grant
    Filed: July 21, 2008
    Date of Patent: June 24, 2014
    Assignee: Innospec Limited
    Inventors: Matthew Robert Giles, Nicholas John Dixon
  • Patent number: 8720436
    Abstract: Gel strips containing reactants capable of reacting to form nitric oxide are maintained separate until application. Upon application, the gel strips are placed in contact with one another, and may mix, or operate by diffusion, to deliver nitric oxide directly to the stream of breathing air of a user. Adhesive strips bonded to a substrate supporting the gel strips may provide for securing the nitric oxide generator directly to an upper lip of a user for breathing the nitric oxide through the nostrils.
    Type: Grant
    Filed: January 28, 2009
    Date of Patent: May 13, 2014
    Assignee: Genosys, Inc.
    Inventor: Christie M. Jones
  • Patent number: 8703053
    Abstract: Antiseptic compositions comprising at least one salt of EDTA are disclosed. These compositions have broad spectrum antimicrobial and antifungal activity and they also have anticoagulant properties. The antiseptic compositions have also demonstrated activity in penetrating and breaking down microbial slime, or biofilms. They are safe for human and medical uses and may be used as prophylactic preparations to prevent infection, or to reduce the proliferation of and/or eliminate existing or established infections.
    Type: Grant
    Filed: July 15, 2013
    Date of Patent: April 22, 2014
    Inventors: Peter Kite, David Hatton
  • Publication number: 20140024719
    Abstract: Antiseptic compositions comprising at least one salt of EDTA are disclosed. These compositions have broad spectrum antimicrobial and antifungal activity and they also have anticoagulant properties. The antiseptic compositions have also demonstrated activity in penetrating and breaking down microbial slime, or biofilms. They are safe for human and medical uses and may be used as prophylactic preparations to prevent infection, or to reduce the proliferation of and/or eliminate existing or established infections.
    Type: Application
    Filed: July 15, 2013
    Publication date: January 23, 2014
    Inventors: Peter Kite, David Hatton
  • Publication number: 20140017338
    Abstract: A composition, system and method for modifying an olfactory response to an odorant is disclosed. In some embodiments, the composition includes crystalline metal nanoparticles dispersed in an aqueous medium. The composition is applied to olfactory tissues using a suitable applicator or dispenser. The metal nanoparticles are believed to interact with a G-protein coupled to receptor located in the cilia to moderate (enhance or reduce) sensitivity or ability to smell particular odorants. In accordance with an embodiment of the invention, the composition includes one or more odorants.
    Type: Application
    Filed: September 17, 2013
    Publication date: January 16, 2014
    Applicant: Auburn University
    Inventors: Vitaly J. Vodyanoy, Nilmini Viswaprakash, Ludmila Petrovna Globa, Edward E. Morrison
  • Publication number: 20130337085
    Abstract: The subject matter of the present invention is in particular the use of an amino acid sequence of IDE, or of an analogue or fragment thereof, or of at least one nucleic acid sequence encoding this sequence, as a biomarker, or as an active agent, with regard to a dandruff condition of the scalp.
    Type: Application
    Filed: December 12, 2011
    Publication date: December 19, 2013
    Applicant: L'oreal
    Inventors: Caroline Delattre, Philemon Sirven, Dominique Bernard
  • Publication number: 20130315981
    Abstract: The present invention is a method of increasing lipolysis in an adipose tissue of a mammal comprising delivering to macrophages at the adipose tissue of the mammal an effective amount of an agent which reduces the concentration of macrophages at the adipose tissue of the mammal, thereby increasing lipolysis in the adipose tissue of the mammal.
    Type: Application
    Filed: June 22, 2011
    Publication date: November 28, 2013
    Applicant: The Trustees of Columbia University in the City of New York
    Inventors: Anthony W. Ferrante, JR., Aliki Kosteli
  • Publication number: 20130310732
    Abstract: Iontophoresis for delivering ophthalmic compositions (in particular. collyriums) preferably containing riboflavin, or other cross-linking agents, designed to imbibe the corneal stroma in the practice of the corneal collagen cross-linking (CXL) for the keratoconus treatment, and the corresponding ophthalmic compositions adapted to be administrated by iontophoresis in the treatment of keratoconus by corneal collagen cross-linking. Additionally, an ophthalmic composition for the treatment of keratoconus by corneal iontophoresis characterized by the fact that it includes cross-linking agents having buffering properties and whose initial pH value is included between 5 and 6, and/or bio-enhancers, and/or photo-enhancers.
    Type: Application
    Filed: January 12, 2011
    Publication date: November 21, 2013
    Applicant: SOOFT ITALIA SPA
    Inventors: Fulvio Foschini, Pierre Roy, Edoardo Stagni, Giovanni Cavallo, Giulio Luciani
  • Patent number: 8580854
    Abstract: Accelerated formation of advanced glycation/lipoxidation end products (AGEs/ALEs) has been implicated in the pathogenesis of various diabetic complications. Several natural and synthetic compounds have been proposed and tested as inhibitors of AGE/ALE formation. We have previously reported the therapeutic effects of several new AGE/ALE inhibitors on the prevention of nephropathy and dyslipidemia in streptozotocin (STZ)-induced diabetic rats. In this study, we investigated the effects of various concentrations of LR-90 on the progression of renal disease and its effects on AGE and receptor for AGE (RAGE) protein expression on the kidneys of diabetic STZ-rats. In vitro studies were also performed to determine if LR-90 could inhibit the expression of various pro-inflammatory mediators in human monocytic cells.
    Type: Grant
    Filed: November 9, 2006
    Date of Patent: November 12, 2013
    Assignee: City of Hope
    Inventors: Samuel Rahbar, Rama Natarajan
  • Publication number: 20130251815
    Abstract: The present disclosure is directed to compositions comprising encapsulated particles of diethylenetriaminepentaacetate (DTPA) and a zinc salt such as zinc acetate, and to pharmaceutical compositions comprising such encapsulated compositions. The present disclosure is also directed to methods of treatment by administering an effective amount of the compositions and pharmaceutical compositions of the present disclosure, to methods of making such encapsulated particle compositions, and to methods of making the corresponding pharmaceutical compositions.
    Type: Application
    Filed: March 14, 2013
    Publication date: September 26, 2013
    Inventor: James David Talton
  • Publication number: 20130225517
    Abstract: The invention provides compounds of formula I: or salts thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula I and therapeutic methods for treating cancer.
    Type: Application
    Filed: February 22, 2013
    Publication date: August 29, 2013
    Applicant: University of Iowa Research Foundation
    Inventor: University of Iowa Research Foundation
  • Publication number: 20130209433
    Abstract: Methods for reducing peripheral blood glucose levels, food intake, glucose production, gluconeogenesis, triglyceride levels, and low density lipoprotein (VLDL) levels in mammals are provided. Also provided are methods of increasing glucose production and food intake in mammals. Further provided are methods of treating a disorder selected from the group consisting of obesity, type 2 diabetes, type 1 diabetes, hyperglycemia, insulin resistance, glucose intolerance, leptin resistance, metabolic syndrome, heart failure, ischemia, coronary heart disease, familial lipoprotein lipase deficiency, hypopituitarism, hyperlipidemia, hypertriglyceridemia, hyper-VLDLemia, atherosclerosis, hypercholesterolemia, hypertension, and any combination of the foregoing. The methods involve manipulations of amino acid presence or metabolism in the hypothalamus of the mammal.
    Type: Application
    Filed: December 12, 2012
    Publication date: August 15, 2013
    Applicant: Albert Einstein College of Medicine of Yeshiva University
    Inventor: Albert Einstein College of Medicine of Yeshiva University
  • Patent number: 8507459
    Abstract: The present invention relates to the novel use of an adenosine aspartate product for the formulation of a drug intended to prevent the development of preneoplastic lesions and to reverse some types of cancer, particularly liver cancer, providing chemoprotection, preventing myelotoxic effects.
    Type: Grant
    Filed: August 21, 2008
    Date of Patent: August 13, 2013
    Assignee: Universidad Nacional Autonnoma de Mexico
    Inventors: Victoria-Eugenia Chagoya-Hazas, Rolando-Efraín Hernandez Muñoz, Saúl Villa-Treviño
  • Patent number: 8426474
    Abstract: Novel wash and carrier solutions ideally suited for topical administration (e.g., as wash solutions and as carrier solutions). The solutions described herein are non-toxic, non-irritating, isotonic, possess non-specific broad-spectrum antimicrobial properties, and have an alkaline pH. Also disclosed are sterile preparations of the solutions and methods of using the same.
    Type: Grant
    Filed: March 15, 2011
    Date of Patent: April 23, 2013
    Assignee: Teva Animal Health, Inc.
    Inventors: Richard Farng, Steven Mrha
  • Publication number: 20130095110
    Abstract: The present invention is directed to KIAA1199, which is a novel factor involved in decomposition of hyaluronic acid, and to use thereof. More specifically, the invention is directed to a hyaluronic acid decomposition-promoting agent containing the KIAA1199 gene and a protein encoded by the gene; to a hyaluronic acid decomposition-inhibiting agent characterized by inhibiting the activity or expression thereof (including an siRNA or a monoclonal antibody); and to a method for screening a novel hyaluronic acid decomposition-controlling agent, in which the method contains employing the expression of KIAA1199 as an index.
    Type: Application
    Filed: June 3, 2011
    Publication date: April 18, 2013
    Applicant: KAO CORPORATION
    Inventors: Hiroyuki Yoshida, Shintaro Inoue, Shingo Sakai, Aya Nagaoka
  • Publication number: 20130089602
    Abstract: An enhanced chelator includes a chelating agent and a volatile material encapsulated in a biologically benign microcapsule. The enhanced chelator possesses significantly improved shelf-life in aqueous biological buffer solutions because the chelating agent is encapsulated in the microcapsule and, therefore, separated from solution components with which the chelating agent would react. The enhanced chelator is activated at a predetermined elevated temperature defined by the boiling point of the volatile material. At this predetermined elevated temperature, the volatile material exerts a vapor pressure sufficient to rupture the microcapsule and thereby release the chelating agent from the microcapsule. In one embodiment, a manganese chelator such as ethylene glycol tetraacetic acid (EGTA) is solubilized in ethanol and encapsulated in a poly(lactic-co-glycolide) (PLGA) microsphere. Upon heating to 80° C.
    Type: Application
    Filed: October 10, 2011
    Publication date: April 11, 2013
    Applicant: INTERNATIONAL BUSINESS MACHINES CORPORATION
    Inventors: Dylan J. Boday, Joseph Kuczynski, Robert E. Meyer, III
  • Publication number: 20130072491
    Abstract: An object is to provide a CaSR agonist agent that has excellent CaSR agonist effects, and particularly, a pharmaceutical product that can prevent or remedy diabetes or obesity by the effect of CaSR activation. The aforementioned object is achieved by a composition that contains a compound represented by the following General Formula (I) or a salt thereof (refer to the Description for the definitions of the symbols used in the formula).
    Type: Application
    Filed: August 31, 2012
    Publication date: March 21, 2013
    Applicant: Ajinomoto Co., Inc.
    Inventors: Reiko YASUDA, Yuzuru Eto, Yoshiro Kitahara
  • Patent number: 8394401
    Abstract: In this application, an antiobesity or antihyperlipidemic food, feeding stuff or supplement containing lysine component(s) that is characterized in that said food, feeding stuff or supplement contains lysine component(s) at such rate that 40 to 160 mg in terms of free-form lysine should be taken in per kg of body weight per day, under diet conditions under which the daily protein energy composition is 20% or less, and an antiobesity or antihyperlipidemic food, feeding stuff or supplement containing lysine component(s) that is characterized by containing said lysine component(s) in an amount of 0.8 to 3.0 wt % in terms of free-form lysine on the basis of the dry matter and having a protein energy composition of 20% or less are disclosed.
    Type: Grant
    Filed: April 27, 2005
    Date of Patent: March 12, 2013
    Assignee: Ajinomoto Co., Inc.
    Inventors: Yuri Hirabayashi, Hitoshi Murakami, Hisamine Kobayashi, Takeo Ueda